title: [Retigabine - a new antiepileptic drug with a different mechanism of action].
abstract: Retigabine belongs to a new generation of antiepileptic drugs. Its mechanism of action is different from that previously known. Retigabine opens potassium channels of subfamily Kv 7, especially Kv 7.2 and Kv 7.3. The drug enhances GABA-ergic transmission. It is well absorbed from the digestive system and undergoes metabolism via glucuronidation and acetylation. There is no interaction between retigabine and other antiepileptic drugs except lamotrigine. The drug has been registered as treatment of partial onset seizures with or without secondary generalization in adults. The efficacy of retigabine is being tested in other types of seizures and disorders characterized by neuronal hyperexcitability. Neuroprotective activity of retigabine is also being researched.
authors.affiliation: Zakład Farmakodynamiki Uniwersytetu Medycznego w Łodzi.
authors.forename: Ewa
authors.initials: E
authors.lastname: Zwierzyńska
authors.forename: Bogusława
authors.initials: B
authors.lastname: Pietrzak
mesh_terms: D000328:Adult; D000927:Anticonvulsants / Q000494:pharmacology*; D002219:Carbamates / Q000494:pharmacology*; D004347:Drug Interactions; D018757:GABA Modulators / Q000494:pharmacology; D006801:Humans; D000077213:Lamotrigine; D049990:Membrane Transport Modulators / Q000494:pharmacology*; D010655:Phenylenediamines / Q000494:pharmacology*; D015221:Potassium Channels / Q000187:drug effects; D012640:Seizures / Q000188:drug therapy*; D014227:Triazines / Q000494:pharmacology
chemical_list: D000927:Anticonvulsants; D002219:Carbamates; D018757:GABA Modulators; D049990:Membrane Transport Modulators; D010655:Phenylenediamines; D015221:Potassium Channels; D014227:Triazines; C101866:ezogabine; D000077213:Lamotrigine